Table 1.
Patient characteristics
| Nivolumab–ipilimumab (n = 10) Median (range) or n (%) |
Nivolumab–ipilimumab plus CBM588 (n = 19) Median (range) or n (%) |
|
|---|---|---|
| Age (years) | 64 (45–79) | 66 (45–90) |
| Gender | ||
| Male | 8 (80) | 13 (68) |
| Female | 2 (20) | 6 (32) |
| Race | ||
| White | 9 (90) | 17 (89) |
| Asian | 1 (10) | 2 (11) |
| Ethnicity | ||
| Non-Hispanic or non-Latinx | 6 (60) | 12 (63) |
| Hispanic or Latinx | 4 (40) | 7 (37) |
| Histologic subtype | ||
| Clear cell | 7 (70) | 12 (63) |
| Clear cell with sarcomatoid features | 2 (20) | 5 (26) |
| Papillary with sarcomatoid features | 1 (10) | 1 (5) |
| Sarcomatoid dedifferentiation | – | 1 (5) |
| IMDC prognostic risk | ||
| Intermediate | 7 (70) | 17 (89) |
| Poor | 3 (30) | 2 (11) |
| Previous nephrectomy | 4 (40) | 9 (47) |
| Number of metastatic sites | ||
| ≥2 | 10 (100) | 19 (100) |
| Most common metastatic sites | ||
| Lung | 6 (60) | 13 (68) |
| Lymph node | 7 (70) | 8 (42) |
| Bone | 4 (40) | 7 (37) |
| Soft tissue | 3 (30) | 7 (37) |
| Liver | 2 (20) | 3 (16) |
| Pancreas | 1 (10) | 3 (16) |
IMDC, International mRCC Database Consortium.